en · de · es · fr · pt
analytical-notes.peptides9002.com › Data › Melanotan-2 Identity And Receptor Pharmacology — Practical Notes

Melanotan-2 Identity And Receptor Pharmacology — Practical Notes

By Editorial Desk · published 2026-01-24 · last reviewed 2026-02-22 · Data

afamelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-02-22 and is reviewed periodically as new material appears.

Melanotan-2 Identity and Receptor Pharmacology

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Melanotan-2 Structure and Receptor Pharmacology

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

Melanotan-2 at a glance

PropertyValueNotes
Common synonymsMelanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amideNaming follows peptide convention; the numeral distinguishes it from melanotan-1
Molecular formulaC50H69N15O9Includes the lactam bridge; no counter-ion assumed
Monoisotopic mass1023.53 DaFree base; salts and counter-ions shift the observed value
AppearanceWhite to off-white lyophilised powderBatch-to-batch colour variation is not itself proof of impurity
Typical analytical methodRP-HPLC purity determination with ESI-MS identity confirmationRetention time alone does not establish sequence identity

Identity and Chemical Background

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

Related pages on this site

Supporting material

They further demonstrated that increased hepatic acetyl-CoA and glycerol flux—resulting from white adipose tissue inflammation—are key drivers of elevated gluconeogenesis in rodent models of type 2 diabetes (T2D). Based on the sn-1,2 DAG–nPKC hypothesis, Shulman's laboratory developed liver-targeted mitochondrial protonophores that reduce hepatic steatosis, insulin resistance, inflammation, and fibrosis in rodent and nonhuman primate models of MASLD and MASH. These compounds have advanced to clinical evaluation.

An OECD proposal to allocate multinational profits (for taxing purposes) to countries where they do business, by a formula, including to markets which multinationals sell into without a physical presence. This is hoped to eliminate the need for Digital Services Tax implemented by several countries, including France. There are exclusions and minimum thresholds, including banking and extractive industries. The proposal involves allocating only residual profit (i.e., profits above what is established through transfer pricing, thus creating a hybrid mechanism). This is essentially no change to what is currently allowed (routine profits allocated using transfer pricing + residual profits allocated through profit split). Pillar 2

==== Fertilization ==== Cephalopods are not broadcast spawners. During the process of fertilization, the females use sperm provided by the male via external fertilization. Internal fertilization is seen only in octopuses. The initiation of copulation begins when the male catches a female and wraps his arm around her, either in a "male to female neck" position or mouth to mouth position, depending on the species. The males then initiate the process of fertilization by contracting their mantle several times to release the spermatozoa. Cephalopods often mate several times, which influences males to mate longer with females that have previously, nearly tripling the number of contractions of the mantle. To ensure the fertilization of the eggs, female cephalopods release a sperm-attracting peptide through the gelatinous layers of the egg to direct the spermatozoa. Female cephalopods lay eggs in clutches; each egg is composed of a protective coat to ensure the safety of the developing embryo when released into the water column. Reproductive strategies differ between cephalopod species. In the giant Pacific octopus, large eggs are laid in a den; it will often take several days to lay all of them. Once the eggs are released and normally attached to a sheltered substrate, the female usually die shortly after, but octopuses and a few squids will look after their eggs afterwards.

study done in 2000 had different results which found that many fewer children responded as being abused by a stepparent. Economic factors could also play a role in the abuse of stepchildren. In places with higher levels of social strain, abuse may be more prevalent or more violent. Other studies of census data and child neglect and abuse records have found that stepparents may be over-represented in abuse figures. They have found that when the data is balanced, biological parents have a much higher rate of abuse than stepparents do. There is little research in the field of parental abuse by children in concern with stepchildren abusing stepparents. The abuse of stepchildren by their siblings is also a topic with little research.

==== Dietary recommendations ==== The U.S. Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for iron in 2001. The current EAR for iron for women ages 14‍–‍18 is 7.9 mg/day, 8.1 mg/day for ages 19‍–‍50 and 5.0 mg/day thereafter (postmenopause). For men, the EAR is 6.0 mg/day for ages 19 and up. The RDA is 15.0 mg/day for women ages 15‍–‍18, 18.0 mg/day for ages 19‍–‍50 and 8.0 mg/day thereafter. For men, 8.0 mg/day for ages 19 and up. RDAs are higher than EARs so as to identify amounts that will cover people with higher-than-average requirements. RDA for pregnancy is 27 mg/day and, for lactation, 9 mg/day. For children ages 1‍–‍3 years 7 mg/day, 10 mg/day for ages 4–8 and 8 mg/day for ages 9‍–‍13. As for safety, the IOM also sets Tolerable upper intake levels (ULs) for vitamins and minerals when evidence is sufficient. In the case of iron, the UL is set at 45 mg/day. Collectively the EARs, RDAs and ULs are referred to as Dietary Reference Intakes. The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in the United States. For women the PRI is 13 mg/day ages 15‍–‍17 years, 16 mg/day for women ages 18 and up who are premenopausal and 11 mg/day postmenopausal. For pregnancy and lactation, 16 mg/day. For men the PRI is 11 mg/day ages 15 and older. For children ages 1 to 14, the PRI increases from 7 to 11 mg/day.

Sources: en.wikipedia.org

Supporting material

The subsequent buildup of urea in the inner medulla is critical to the process of urinary concentration. Reabsorption is also increased by volume contraction, reduced renal plasma flow as in congestive heart failure, and decreased glomerular filtration. Creatinine formation begins with the transamidination from arginine to glycine to form glycocyamine or guanidoacetic acid (GAA). This reaction occurs primarily in the kidneys, but also in the mucosa of the small intestine and the pancreas. The GAA is transported to the liver where it is methylated by S-adenosyl methionine (SAM) to form creatine. Creatine enters the circulation, and 90% of it is taken up and stored by muscle tissue.

City Hall of Valencina - Official site of the City Hall of Valencina de la Concepción Valencina de la Concepción - Sistema de Información Multiterritorial de Andalucía - 2011 archive Valencina: A copper age polity (2025) Urbanismo en Valencina - Information about town planning in Valencina de la Concepción Dolmen of Matarrubilla - Information about the dolmen of Matarrubilla - 2022 archive Dolmen of La Pastora - Information about the dolmen of La Pastora - 2022 archive Studies in Iberian Archaeoastronomy: (8) Orientations of Megalithic and Tholos Tombs of Portugal and Southwest Spain

Officials in the Truman administration placed responsibility for postwar tensions on the Soviets, claiming that Stalin had violated promises made at Yalta, pursued a policy of expansionism in Eastern Europe, and conspired to spread communism throughout the world. Historians associated with the "Wisconsin School" of diplomatic history such as Williams, however, placed responsibility for the breakdown of postwar peace mostly on the US, citing a range of US efforts to isolate and confront the Soviet Union well before the end of World War II. According to Williams and later writers influenced by his work—such as LaFeber, author of the popular survey text America, Russia, and the Cold War (published in ten editions between 1967 and 2006)—US policymakers shared an overarching concern with maintaining capitalism domestically. In order to ensure this goal, they pursued a policy of ensuring an "Open Door" to foreign markets for US business and agriculture across the world. From this perspective, a growing economy domestically went hand-in-hand with the consolidation of US power internationally. Williams and LaFeber also dismissed the assumption that Soviet leaders were committed to postwar "expansionism". They cited evidence that Soviet Union's occupation of Eastern Europe had a defensive rationale, and Soviet leaders saw themselves as attempting to avoid encirclement by the United States and its allies.

=== Reproduction === It has been postulated that MCH has a modulatory role with the release of Luteinizing Hormone (LH) either by directly acting on the pituitary gland or indirectly by affecting Gonadotropin-releasing hormone (GNRH) in the hypothalamus. Estrogen seems to be necessary in order for MCH to affect reproduction.

Sources: en.wikipedia.org

Supporting material

=== Management === The management of uterine prolapse may be conservative or surgical, depending on factors such as personal preference, symptom severity, and extent of prolapse. Additionally, management of existing medical conditions that can contribute to prolapse, such as chronic lung conditions or obesity, are important to prevent progression of uterine prolapse and reduce symptom burden.

== Technique == The technique initially incubates a small amount of abnormal prion with an excess of normal protein, so that some conversion takes place. The growing chain of misfolded protein is then blasted with ultrasound, breaking it down into smaller chains and so rapidly increasing the amount of abnormal protein available to cause conversions. By repeating the cycle, the mass of normal protein is rapidly changed into the prion being tested for.

Oxymatrine (matrine oxide, matrine N-oxide, matrine 1-oxide) is one of many quinolizidine alkaloid compounds extracted from the root of Sophora flavescens, a Chinese herb. It is very similar in structure to matrine, which has one less oxygen atom, and oxymatrine is partially metabolized to matrine in the human gut. Oxymatrine has a variety of effects in vitro and in animal models, including protection against apoptosis, tumor and fibrotic tissue development, and inflammation. Furthermore, oxymatrine has been shown to decrease cardiac ischemia (decreased blood perfusion), myocardial injury, arrhythmias (irregular heartbeats), and improve heart failure by increasing cardiac function.

CH3C(O)CO−2 → "CH3CO−" + CO2 This irreversible reaction is catalyzed by the pyruvate dehydrogenase complex. It consists of three enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2), dihydrolipoamide dehydrogenase (E3), six cofactors: thiamine pyrophosphate (TPP), lipoamide, coenzyme A (CoA), flavin adenine dinucleotide (FAD), magnesium ion, and one co-substrate: nicotinamide adenine dinucleotide (NAD+). Pyruvate converts the thiazole ring of TPP to its hydroxyethyl derivative, concomitant with decarboxylation. With the catalysis of E2, TPP-CH(OH)CH3 reacts with the S-S bond of lipoamide to produce thioester bond (acetyl dihydrolipoamide. The acetyl reacts with CoA-SH to give Acetyl-CoA and dihydrolipoamide. The latter is oxidized to lipoamide (with S-S bond) by FAD.

EPA – Radionuclides – EPA's Radiation Protection Program: Information. FDA – Radionuclides – FDA's Radiation Protection Program: Information. Interactive Chart of Nuclides – A chart of all nuclides National Isotope Development Center – U.S. Government source of radionuclides – production, research, development, distribution, and information The Live Chart of Nuclides – IAEA Radionuclides production simulator – IAEA

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

How does it differ from the natural hormone?

The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.

Does it hold any regulatory approval?

No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

Network